| Literature DB >> 34021002 |
Olivier Delattre1, Dimiter S Dimitrov2, Hai-Feng Zhang3,4, Christopher S Hughes3,4, Wei Li2, Jian-Zhong He5, Didier Surdez1,6, Amal M El-Naggar3,4, Hongwei Cheng4,7, Anna Prudova4,8, Alberto Delaidelli3,4, Gian Luca Negri8, Xiaojun Li4, Maj Sofie Ørum-Madsen9, Michael M Lizardo4, Htoo Zarni Oo9, Shane Colborne8, Taras Shyp3,4, Renata Scopim-Ribeiro3,4, Colin A Hammond10, Anne-Chloe Dhez3,4, Sofya Langman3,4, Jonathan K M Lim3,4, Sonia H Y Kung9, Amy Li3,4, Anne Steino4, Mads Daugaard9,4, Seth J Parker3,11, Ramon I Klein Geltink3,11, Rimas J Orentas12,4, Li-Yan Xu5, Gregg B Morin8,13, Poul H Sorensen14,4.
Abstract
Cancer cells must overcome anoikis (detachment-induced death) to successfully metastasize. Using proteomic screens, we found that distinct oncoproteins upregulate IL1 receptor accessory protein (IL1RAP) to suppress anoikis. IL1RAP is directly induced by oncogenic fusions of Ewing sarcoma, a highly metastatic childhood sarcoma. IL1RAP inactivation triggers anoikis and impedes metastatic dissemination of Ewing sarcoma cells. Mechanistically, IL1RAP binds the cell-surface system Xc - transporter to enhance exogenous cystine uptake, thereby replenishing cysteine and the glutathione antioxidant. Under cystine depletion, IL1RAP induces cystathionine gamma lyase (CTH) to activate the transsulfuration pathway for de novo cysteine synthesis. Therefore, IL1RAP maintains cyst(e)ine and glutathione pools, which are vital for redox homeostasis and anoikis resistance. IL1RAP is minimally expressed in pediatric and adult normal tissues, and human anti-IL1RAP antibodies induce potent antibody-dependent cellular cytotoxicity of Ewing sarcoma cells. Therefore, we define IL1RAP as a new cell-surface target in Ewing sarcoma, which is potentially exploitable for immunotherapy. SIGNIFICANCE: Here, we identify cell-surface protein IL1RAP as a key driver of metastasis in Ewing sarcoma, a highly aggressive childhood sarcoma. Minimal expression in pediatric and adult normal tissues nominates IL1RAP as a promising target for immunotherapy.See related commentary by Yoon and DeNicola, p. 2679.This article is highlighted in the In This Issue feature, p. 2659. ©2021 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34021002 PMCID: PMC8563374 DOI: 10.1158/2159-8290.CD-20-1690
Source DB: PubMed Journal: Cancer Discov ISSN: 2159-8274 Impact factor: 39.397